Role of osteopontin in cellular signaling and toxicant injury

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 723-749

  Denhardt, D T ^a   Giachelli, C M ^a   Rittling, S R ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Bone remodeling; Cell attachment; Cell survival; Cellular immunity; Inflammation; Metastasis

Indexed keywords

CYTOKINE; HERMES ANTIGEN; INTEGRIN; OSTEOPONTIN; TOXIC SUBSTANCE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BONE REMODELING; CANCER CELL; CARCINOGENESIS; CELL ADHESION; CELL SURVIVAL; CELLULAR IMMUNITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; INFLAMMATION; MACROPHAGE MIGRATION; METASTASIS; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE DISEASES; HUMANS; NEOPLASMS; OSTEOPONTIN; RECEPTORS, CYTOKINE; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION; TOXINS, BIOLOGICAL;

EID: 0035028793     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.723     Document Type: Review

References (134)

1. Osteopontin, a coordinator of host defense system: A cytokine or an extracellular adhesive protein?
2. Osteopontin: Potential roles in vascular function and dystrophic calcification
3. Osteopontin (OPN) function in pathology: Lessons from OPN-deficient mice
4. Osteopontin
5. Osteopontin expression and function: Role in bone remodeling
6. Crosslinking of osteopontin by tissue transglutaminase increases its collagen binding properties
7. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro
8. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by β3 integrin
9. 1 integrin
10. 1 integrin
11. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin
12. 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin
13. Receptor-ligand interaction between CD44 and osteopontin (ETA-1)
14. CD44 is not an adhesive receptor for osteopontin
15. CD44 variants but not CD44s cooperate with betalcontaining integrins to permit cells to bind to osteopontin independently of arginineglycine-aspartic acid, thereby stimulating cell motility and chemotaxis
16. Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration
17. Intracellular OPN is an integral component of the CD44-ERM complex involved in cell migration
18. Casein kinase 2 phosphorylation of recombinant rat osteopontin enhances adhesion of osteoclasts but not osteoblasts
19. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity
20. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro
21. Integrin-mediated signaling in the regulation of osteoclast adhesion and activation
22. 3 integrin stimulates immediate cell signals in osteoclasts
23. Immediate cell signal by bone-related peptides in human osteoclast-like cells
24. i in rat osteoclasts and mouse-derived osteoclast-like cells
25. v subunit
26. Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-liydroxyl kinase
27. c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase
28. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength
29. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption
30. 3 integrin-induced endothelial cell survival
31. 3-induced, NFkappaB-dependent survival factor for endothelial cells
32. Osteopontin-induced modifications of cellular functions
33. Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor
34. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth
35. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection
36. Polyclonal B-cell activation by the Eta-1 cytokine and the development of autoimmune disease
37. In vivo cytokine gene expression in various T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse
38. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis
39. Delayed expression of osteopontin after focal stroke in the rat
40. Transient upregulation of osteopontin mRNA in hippocampus and striatum following global forebrain ischemia in rats
41. Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: A possible factor for macrophage migration into hepatic necrotic areas
42. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo
43. Obstructive uropathy in the mouse: Role of osteopontin in interstitial fibrosis and apoptosis
44. A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat
45. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo
46. A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis
47. Altered wound healing in mice lacking a functional osteopontin gene (spp1)
48. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo
49. Expression of wild-type and mutated rabbit osteopontin in Escherichia coli, and their effects on adhesion and migration of P388D1 cells
50. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells
51. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW 264.7 macrophages
52. Secretion of osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: A potential requirement for macrophage adhesion and phagocytosis
53. Differential screening identifies genetic markers of monocyte to macrophage maturation
54. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue
55. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase
56. Regulation of NO synthesis induced by inflammatory mediators in RAW264.7 cells: Collagen prevents inhibition by osteopontin
57. Macrophages express osteopontin during repair of myocardial necrosis
58. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin
59. The role of osteopontin in the development of granulomatous lesions in lung
60. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR)
61. Molecular and cellular biology of osteopontin
62. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation
63. Differential processing of osteopontin characterizes the proliferative vascular smooth muscle cell phenotype induced by allylamine
64. Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells
65. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin
66. Osteopontin in chronic puromycin aminonucleoside nephrosis
67. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion
68. Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration in rats
69. Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury
70. Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat
71. Upregulation of osteopontin in ischemia-induced renal failure in rats: A role for ET-1?
72. IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat
73. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene
74. Lack of in vivo function of osteopontin in experimental anti-GBM nephritis
75. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome
76. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack
77. Osteopontin in skeletal tissue homeostasis: An emerging picture of the autocrine/paracrine functions of the extracellular matrix
78. Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: Ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair
79. Changes in biological activity of bone cells in ovariectomized rats revealed by in situ hybridization
80. Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: Demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy
81. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro
82. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption
83. Osteopontin facilitates angiogenesis, accumulation of osteoclasts and resorption in ectopic bone
84. Mechanical stimulation of osteopontin mRNA expression and synthesis in bone cell cultures
85. Role of osteopontin in bone remodeling caused by mechanical stress
86. Mechanotransduction in bone: Role of the lacuno-canalicular network
87. Evidence for the formation of a complex between osteopontin and osteocalcin
88. Electrophysiological responses of human bone cells to mechanical stimulation: Evidence for specific integrin function in mechanotransduction
89. Parathyroid hormone-activated volume-sensitive calcium influx pathways in mechanically loaded osteocytes
90. Control of bone formation and resorption: Biological and clinical perspective
91. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption
92. How the osteoclast degrades bone
93. Cell biology of the osteoclast
94. Cytokines, bone remodeling, and estrogen deficiency: A 1998 update
95. Transformed mammalian cells secrete specific proteins and phosphoproteins
96. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells
97. Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: Induction is stable at high, but not low, cell densities
98. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation
99. Osteopontin expression and distribution in human carcinomas
100. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer
101. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma
102. Co-expression of osteopontin and CD44v9 in gastric cancer
103. Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces
104. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer
105. Expression of bone matrix messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci
106. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer
107. Clacitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancer
108. Osteopontin expression in a group of lymph node negative breast cancer patients
109. Osteopontin expression in mammary gland development and tumorigenesis
110. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival
111. The LCC-15 MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype
112. Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines
113. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells
114. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model
115. Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line
116. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene
117. Mammary tumorigenesis is normal in the absence of osteopontin
118. Specific reduction in OPN synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts
119. Expression of antisense osteopontin mRNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells
120. 3 in smooth muscle migration to osteopontin in vitro
121. 3 integrin, osteopontin, and thrombin
122. Inhibition of Arg-Gly-Asp(RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin
123. 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate arg-gly-asp-dependent endothelial migration in vitro
124. 3 for angiogenesis
125. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
126. Requirement for Valphal4 NKT cells in IL-12-mediated rejection of tumors
127. Interleukin-12 as an adjuvant for cancer immunotherapy
128. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site
129. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role